Hoffman I F, Jere C S, Taylor T E, Munthali P, Dyer J R, Wirima J J, Rogerson S J, Kumwenda N, Eron J J, Fiscus S A, Chakraborty H, Taha T E, Cohen M S, Molyneux M E
University of North Carolina, Division of Infectious Diseases, Chapel Hill, USA.
AIDS. 1999 Mar 11;13(4):487-94. doi: 10.1097/00002030-199903110-00007.
This study was undertaken to determine the relative effect of malaria infection on HIV concentration in blood plasma, and prospectively to monitor viral concentrations after antimalarial therapy.
A prospective, double cohort study was designed to compare the blood HIV-1 RNA concentrations of HIV-positive individuals with and without acute malaria illness. Subjects were followed for 4 weeks after successful malaria therapy, or for 4 weeks from enrollment (controls).
Malawian adults with symptomatic Plasmodium falciparum parasitemia (malaria group) and asymptomatic, aparasitemic blood donors (control group) were tested for HIV-1 antibodies to identify appropriate study groups. The malaria group received antimalarial chemotherapy only and were followed with sequential blood films. In both groups, blood plasma HIV-1 RNA viral concentrations were determined at enrollment and again at 1, 2 and 4 weeks.
Forty-seven malaria patients and 42 blood donors were enrolled. At enrollment blood plasma HIV-1 RNA concentrations were approximately sevenfold higher in patients with malaria than in blood donors (medians 15.1 x 10(4) and 2.24 x 10(4) copies/ml, respectively, P = 0.0001). No significant changes in median HIV-1 concentrations occurred in the 21 blood donors followed to week 4 (P = 0.68). In the 27 subjects successfully treated for malaria who were followed to week 4, a reduction in plasma HIV-1 RNA was observed from a median of 19.1 x 10(4) RNA copies/ml at enrollment, to 12.0 x 10(4) copies/ml at week 4, (P = 0.02). Plasma HIV-1 concentrations remained higher in malaria patients than controls (median 12.0 x 10(4) compared with 4.17 x 10(4) copies/ml, P = 0.086).
HIV-1 blood viral burden is higher in patients with P. falciparum malaria than in controls and this viral burden can, in some patients, be partly reduced with antimalarial therapy.
本研究旨在确定疟疾感染对血浆中HIV浓度的相对影响,并前瞻性地监测抗疟治疗后的病毒浓度。
一项前瞻性双队列研究旨在比较有和没有急性疟疾的HIV阳性个体的血液HIV-1 RNA浓度。成功进行疟疾治疗后,对受试者随访4周,或从入组开始随访4周(对照组)。
对有症状的恶性疟原虫血症的马拉维成年人(疟疾组)和无症状、无寄生虫血症的献血者(对照组)进行HIV-1抗体检测,以确定合适的研究组。疟疾组仅接受抗疟化疗,并通过连续血涂片进行随访。两组在入组时以及第1、2和4周再次测定血浆HIV-1 RNA病毒浓度。
招募了47名疟疾患者和42名献血者。入组时,疟疾患者血浆HIV-1 RNA浓度比献血者高约7倍(中位数分别为15.1×10⁴和2.24×10⁴拷贝/毫升,P = 0.0001)。随访至第4周的21名献血者中,HIV-1浓度中位数无显著变化(P = 0.68)。在随访至第4周的27名成功治疗疟疾的受试者中,观察到血浆HIV-1 RNA从入组时的中位数19.1×10⁴ RNA拷贝/毫升降至第4周的12.0×10⁴拷贝/毫升(P = 0.02)。疟疾患者的血浆HIV-1浓度仍高于对照组(中位数12.0×10⁴与4.17×10⁴拷贝/毫升相比,P = 0.086)。
恶性疟原虫疟疾患者的HIV-1血液病毒载量高于对照组,并且在一些患者中,这种病毒载量可以通过抗疟治疗部分降低。